Clinical TrialApr 14, 2026, 08:02 AM
Grace Therapeutics GTx-104 Phase 3 Trial Shows 19% Hypotension Reduction
AI Summary
Grace Therapeutics announced that its STRIVE-ON Phase 3 Safety Trial for GTx-104 met its primary endpoint, demonstrating a 19% reduction in clinically significant hypotension compared to oral nimodipine in aneurysmal subarachnoid hemorrhage (aSAH) patients. The trial also showed improved functional outcomes and reduced intensive care unit stays for patients receiving GTx-104. These positive results will be presented at the upcoming 2026 American Academy of Neurology annual meeting.
Key Highlights
- GTx-104 reduced clinically significant hypotension by 19% (28% vs 35%) compared to oral nimodipine.
- 54% of GTx-104 patients achieved 95% or higher relative dose intensity vs. 8% for oral nimodipine.
- 29% more GTx-104 patients had favorable functional outcomes at 90 days.
- Patients on GTx-104 experienced fewer ICU readmissions, ICU days, and ventilator days.
- Results will be presented at the 2026 American Academy of Neurology annual meeting on April 21, 2026.